Introduction to Translational Cancer Research

Robert C. Bast Jr., MD, is Director of Translational Cancer Research Career Development programs at UT MD Anderson Cancer Center, where he previously served as Vice President for Translational Research for over two decades. His group discovered the CA125 biomarker for ovarian cancer and pioneered targeted therapy approaches for ovarian and breast cancers. Maurie Markman, MD, is President of Medicine and Science at City of Hope Atlanta, Chicago, and Phoenix. With more than 300 original research articles and over 20 books, he brings four decades of clinical investigation in gynecologic oncology and new drug development from leadership roles at Memorial Sloan-Kettering and MD Anderson. Ernest Hawk, MD, MPH, is Vice President for Cancer Prevention and Head of the Division of Cancer Prevention and Population Sciences at UT MD Anderson Cancer Center. He has authored over 200 original research articles and leads community outreach efforts delivering evidence-based cancer prevention programs to reduce the burden of cancer and its associated risks at the population level.

• Chapter 1: The Challenge of Translational Cancer ResearchRobert C. Bast, Jr., M.D.Chapter 2: Targets for Translation: Cancer Biology and Tumor HeterogeneityRobert C. Bast, Jr., M.D.Chapter 3: Targets for Translation: Tumor Microenvironment and Immunity Mason Ruiz, Ph.D., Zhiqiang An, Ph.D. Anil K. Sood. M.DChapter 4: Molecular DiagnosticsRobert C. Bast, Jr., M.D.Chapter 5: Drug and Biologics DevelopmentRobert C. Bast, Jr., M.D.Chapter 6: Artificial Intelligence and Data Science to Accelerate Drug DevelopmentKaitlyn P Russell, Ph.D. and Bissan Al-Lazikani, Ph.D.Chapter 7: Molecular TherapeuticsRobert C. Bast, Jr., M.D.Chapter 8: The Personalization of Cancer Care: Linking Molecular Diagnostics andMolecular TherapeuticsRobert C. Bast, Jr., M.D.Chapter 9: Cancer PreventionErnest Hawk, M.D.Chapter 10: Multidisciplinary Translational Cancer ResearchMaurie Markman, M.D., Mike White, M.D., Vincent Pagan, M.D., Chad Tang, M.D., and Jonathan Gill, M.D.Chapter 11: Oncologic ImagingVikas Kundra, M.D., Ph.D.Chapter 12: Training, Assembling and Sustaining Teams for Translational Cancer    ResearchRobert C. Bast, Jr., M.D.Chapter 13: Infrastructure for Translational Cancer ResearchRobert C. Bast, Jr, M.D.Chapter 14: The Role of Government in Translational Cancer ResearchErnest Hawk, M.D.Chapter 15: The Role of the FDA in Translational Cancer ResearchMaurie Markman, M.D.Chapter 16: The Role of Pharma and Biotech in Translational Cancer ResearchRobert C. Bast, Jr., M.D.Chapter 17: Funding Translational ResearchRobert C. Bast, Jr., M.D.Chapter 18: The Role of the Community in Translational Cancer ResearchRobert C. Bast, Jr., M.D.Chapter 19: Dissemination and Implementation of Translational Cancer ResearchMaria E. Fernandez, PhD and Mary-Louise E. Millett, MPHChapter 20: Overcoming Cancer Disparities to Achieve Equity through Translational Cancer ResearchInimfon N. Jackson M.D., M.P.H., Ph.D. Christopher R. Flowers, M.D., M.S. and Chijioke C Nze, M.D., M.P.H.Chapter 21: Accelerating Translational Cancer ResearchRobert C, Bast, Jr., M.D.